Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
DESCRIPTION (provided by the applicant): Endothelin-1 (ET-1) and angiotensin II
(AngII) are critical hormones necessary for the appropriate function of the
cardiovascular system, acting centrally as well as peripherally. Both hormonal
systems have been implicated in cardiovascular pathology -- hypertension,
endothelial dysfunction, cardiac hypertrophy and failure. Several isoreceptors
for both ET-1 and AngII have been recently characterized. Of these, the dual
ET-1/AngII receptor, isolated by us via an approach based on and supporting the
molecular recognition theory elucidates novel information providing the bases
for new hypotheses and questions. The long-term objective of this proposal is
to dissect the specific contribution of the ET-l/AngII receptor gene to blood
pressure regulation in normal and pathophysiological states like hypertension.
In this research proposal, we will test the following hypotheses: 1) Based on
our preliminary data showing a) gender-bias o 1I the cosegregation of the ET-II
/AngII receptor locus with hypertension in an F2 (Dahl S x Dahl R) intercross,
and b) structural differences between the Dahl salt-sensitive and the Dahl
salt-resistant rat ET-1/AngII receptors, we hypothesize that the ET-1/AngII
receptor acts in a gender specific manner influencing blood pressure in the
Dahl rat model. 2) Based on the detected abundance of the ET-l/AngII receptor
mRNA in brain and cardiovascular tissues, we hypothesize that this receptor is
a prominent physiologic target for ET- 1 and AngII in these organs, and
therefore plays an important role in blood pressure regulation. Investigating
the following specific aims will test these hypotheses: 1. Gender specific role
of the ET-1/AngII receptor in susceptibility to salt-sensitive hypertension.
1A) Functional characterization of the Dahl S and Dahl R ET-1/AngII receptors
that differ in two amino acids. 1B) Establishment of three inbred trans genie
Dahl S rat lines bearing exogenous Dahl R ET-1/AngII receptor,
Tg[RET-1/AngIIr], and three control Dahl S rat lines bearing exogenous Dahl S
ET- 1/AngIl receptor, Tg[SET- 1/AnglIr], driven by the cognate Dahl R 5'
flanking regulatory region. 1C) Determine the transgenic molecular phenotype,
that is the relative amounts of exogenous (transgenic) Dahl R and Dahl S ET-
1/Angll receptor mRNA and endogenous Dahl S ET-1/AngIl receptor mRNA expression
levels in Tg[RET-1/AngIIr] and Tg[SET-1/AngIIr} rats respectively. 1D)
Determine the physiological effects of the Dahl R and Dahl S ET- 1/AngII
receptor transgene by analyzing differences between age-matched non-transgenic
inbred Dahl S rats (males and females) and transgenic inbred Tg[RET- 1/AnglIr]
and Tg[SET1I AngIIr] Dahl S rat lines with respect to 1) the onset, course and
degree of hypertension; 2) lifespan; 3) severity of hypertensive renal disease.
2. Dissection of physiologic role(s) of the ET-1/AngII receptor. 2A) Tissue
specific, spatial and temporal expression patterns in development of the
ET-1/AngII receptor gene. 2B) Targeted disruption of the ET- 1/AngIl receptor
gene and development of "knockout" mouse model in order to define its
physiologic role in an integrated biologic experimental system. Our proposed
studies will elucidate the physiological role of the ET- 1 /AngII receptor
throughout development. Furthermore, it will demonstrate the gender specific
involvement of the ET- 1/AngII receptor in salt-sensitive hypertension in the
Dahl rat model, thus providing a validated prioritization scheme to investigate
the potential role of this receptor in human essential hypertension.
No Sub Projects information available for 1R01HL069937-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01HL069937-01
Patents
No Patents information available for 1R01HL069937-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01HL069937-01
Clinical Studies
No Clinical Studies information available for 1R01HL069937-01
News and More
Related News Releases
No news release information available for 1R01HL069937-01
History
No Historical information available for 1R01HL069937-01
Similar Projects
No Similar Projects information available for 1R01HL069937-01